ImCyse Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 57

Employees

  • Latest Deal Type
  • Liquidation

ImCyse General Information

Description

Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, enabling physicians to treat and prevent severe chronic diseases caused by disruptions of the immune system.

Contact Information

Website
www.imcyse.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Avenue Pré-Aily 14
  • Angleur
  • 4031 Liege
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Avenue Pré-Aily 14
  • Angleur
  • 4031 Liege
  • Belgium

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImCyse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Bankruptcy: Liquidation 20-Jun-2024 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 03-Feb-2021 Completed Clinical Trials - Phase 2
7. Grant 18-Jun-2019 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 18-Jun-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Nov-2017 Completed Clinical Trials - Phase 2
4. Early Stage VC 27-Aug-2014 Completed Startup
3. Early Stage VC 01-Nov-2012 Completed Startup
2. Early Stage VC 09-Feb-2011 $270K $270K Completed Startup
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view ImCyse’s complete valuation and funding history, request access »

ImCyse Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class B
Class E
Class C
Class B
Class D
Class C
Class E
Class B
Class E 39,168 $24.9 $24.9 1x $24.9 1.34%
Class C 469 $24.9 $24.9 1x $24.9 0.02%
To view ImCyse’s complete cap table history, request access »

ImCyse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines
Drug Discovery
Liege, Belgium
57 As of 2023

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImCyse Competitors (1)

One of ImCyse’s competitors is Crescendo Biologics, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crescendo Biologics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 1 of 1 competitors. Get the full list »

ImCyse Patents

  • 170

    Total Documents Applications and Grants

  • Total Patents Families

  • 80

    Granted

  • 57

    Pending

  • Expiring in next 12 mo

ImCyse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022304222-A9 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021
AU-2022304222-A1 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021
CA-3222570-A1 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021
EP-4362972-A1 Peptides and methods for the treatment of neuromyelitis optica Inactive 29-Jun-2021
US-20240228558-A9 Peptides and methods for the treatment of neuromyelitis optica Inactive 29-Jun-2021 C07K14/47
To view ImCyse’s complete patent history, request access »

ImCyse Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

ImCyse FAQs

  • When was ImCyse founded?

    ImCyse was founded in 2010.

  • Where is ImCyse headquartered?

    ImCyse is headquartered in Liege, Belgium.

  • What is the size of ImCyse?

    ImCyse has 57 total employees.

  • What industry is ImCyse in?

    ImCyse’s primary industry is Drug Discovery.

  • Is ImCyse a private or public company?

    ImCyse is a Private company.

  • What is ImCyse’s current revenue?

    The current revenue for ImCyse is .

  • How much funding has ImCyse raised over time?

    ImCyse has raised $65.4M.

  • Who are ImCyse’s competitors?

    Crescendo Biologics is a competitor of ImCyse.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »